To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
About This Bill
Committee
Latest Action · February 6, 2025
Referred to the House Committee on Energy and Commerce.